Neovascular age-related macular degeneration: Potential therapies

Drugs

Volumn 68, Issue 8, 2008, Pages 1029-1036

  Chappelow, Aimee V ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Age related macular degeneration, treatment; Bevasiranib, therapeutic use; Pazopanib, therapeutic use; Ranibizumab, therapeutic use; Research and development; Sirolimus, therapeutic use; TG 100801, therapeutic use; Vatalanib, therapeutic use

Indexed keywords

AG 013958; AGN 211745; AL 39324; BEVACIZUMAB; BEVASIRANIB; DACLIZUMAB; INFLIXIMAB; JSM 6427; MESSENGER RNA; NICOTINIC RECEPTOR BLOCKING AGENT; PAZOPANIB; PEGAPTANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT PROTEIN; RTP801I 14; SMALL INTERFERING RNA; TG 100801; TG 101095; TRP 801I 14; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR; VASCULOTROPIN TRAP; VATALANIB; VERTEPORFIN;

BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME INHIBITION; HUMAN; HYPERTENSION; MONOTHERAPY; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA DEGRADATION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; EYE PROTEINS; HUMANS; MACULAR DEGENERATION; NERVE GROWTH FACTORS; NICOTINIC ANTAGONISTS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SERPINS; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43749096100     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00002     Document Type: Review

References (39)

1. WHO. Magnitude and causes of visual impairment [fact sheet no. 282]. Geneva: World Health Organization, 2004 Nov [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs282/en/ [Accessed 2008 Feb 8]
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122 (4): 564-72
3. Congdon N, O'Colmain B, Klaver CC, et al., The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122 (4): 477-85
4. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109 (9): 1220-31
5. Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006; 244 (9): 1132-42
6. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113 (6): 992-1001.e6
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-44
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419-31
9. CATT: Lucentis®-Avastin® Trial. Manual of procedures. 2007 Dec. Center for Preventive Ophthalmology and Biostatistics (CPOB) [online]. Available from URL: http://www.med.upenn.edu/cpob/studies/documents/CATTMOP12.17.07.pdf [Accessed 2008 Feb 8]
10. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor Trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113 (9): 1522 e1-14
11. Hariprasad SM. Fluorescein angiographic and OCT outcomes of a phase I, dose-escalation, safety, tolerability, and bioactivity study of intravitreal VEGF Trap in patients with neovascular AMD: The CLEAR-IT 1 Study. Combined Retina Society/Gonin Society Meeting; 2006 Oct 15-20; Cape Town
12. Nguyen Q, Hariprasad S, Browning D, et al. Interim results of a phase I, dose-escalation, safety, tolerability, and bioactivity study of intravitreal VEGF Trap in patients with neovascular age-related macular degeneration: The CLEAR-IT 1 Study [abstract no. E-2868]. Combined Retina Society/Gonin Society Meeting; 2006 Oct 15-20; Cape Town
13. Hariprasad SM, Kaiser P, Slakter J, et al. Optical coherence tomography outcomes of a phase I, dose-escalation, safety, tolerability, and bioactivity study of intravitreal VEGF Trap in patients with neovascular age-related macular degeneration: The CLEAR-IT 1 Study [abstract no. E-1811]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl? arvomtgsearch=true [Accessed 2008 Feb 8]
14. Benz MS, Nguyen QD, Chu K, et al. CLEAR-IT-2: interim results of the phase ii, randomized, controlled dose- and interval-ranging study of repeated intravitreal VEGF Trap administration in patients with neovascular age-related macular degeneration (AMD) [abstract no. E-4549]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl? arvomtgsearch=true [Accessed 2008 Feb 8]
15. Open-label, long-term, safety and tolerability study of intravitreal VEGF Trap-eye in neovascular age-related macular degeneration [ClinicalTrials.gov identifier: NCT00527423]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00527423 [Accessed 2008 Feb 8]
16. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243 (6): 593-600
17. Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE) [ClinicalTrials.govidentifier: NCT00138632]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00138632 [Accessed 2008 Mar 7]
18. A study to evaluate the safety, tolerability and PK of pazopanib eye drops in healthy adult and elderly subjects [ClinicalTrials.gov identifier: NCT00463320]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00463320 [Accessed 2008 Feb 8]
19. Chen ZZ, Mak C, Renick J, et al. A dual VEGFR/JAK2 kinase inhibitor suitable for topical delivery inhibits choroid neovascularization in mice [abstract no. E-1469]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl?.arvomtgsearch=true [Accessed 2008 Feb 8]
20. A phase 1 safety study of TG100801 eye drops in healthy volunteers [ClinicalTrials.gov identifier: NCT00414999]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00414999 [Accessed 2008 Feb 8]
21. Bingaman DP, Gu X, Landers RA, et al. AL-39324 is more potent and efficacious against ocular NV vs. other RTKi's [abstract no. E-1747]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl?.arvomtgsearch=true [Accessed 2008 Feb 8]
22. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43 (7): 2428-34
23. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17 (2): 167-76
24. Heeschen C, Weis M, Aicher A, et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110 (4): 527-36
25. Kengatharan M, Verghese M, Kiuchi K, et al. Nicotinic receptor antagonist mecamylamine reduces laser-induced choroidal neovascularization in C57bl/6j mice [abstract no. E-6016]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl?arvomtgsearch=true [Accessed 2008 Mar 7]
26. CoMentis, Inc. CoMentis initiates phase II clinical trial for AMD eye drop [press release]. 2007 Apr 10
27. Brucker A. Small interfering rna (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. retina society. Combined Retina Society/Gonin Society Meeting; 2006 Oct 15-20; Cape Town
28. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-6
29. Safety and efficacy study evaluating the combination of bevasiranib and Lucentis therapy in wet AMD (COBALT) [ClinicalTrials.gov identifier: NCT00499590]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00499590 [Accessed 2008 Feb 8]
30. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13 (3): 225-34
31. A study using intravitreal injections of a small interfering RNA in patients with age-related macular degeneration [ClinicalTrials.gov identifier: NCT00395057]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00395057 [Accessed 2008 Feb 8]
32. Nozaki M, Raisler BJ, Mett I, et al. RTP801i: a novel antiangiogenic strategy superior to and cooperative with VEGF-A blockade in suppressing CNV [abstract no. E-900]. Invest Ophthalmol Vis Sci 2006; 47 (5) [online]. Available from URL: http://www.iovs.org/search.dtl?.arvomtgsearch=true [Accessed 2008 Feb 8]
33. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8 (2): 128-35
34. Kleinman DM, Kim DD, Nivaggioli T, et al. Sirolimus inhibits VEGF-induced microvascular hyperpermeability [abstract no. E-1422]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl? arvomtgsearch=true [Accessed 2008 Mar 7]
35. Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10: 964-72
36. MacuSight, Inc. MacuSight™ initiates wet age-related macular degeneration study [press release]. 2006 Oct 31
37. Infliximab, sirolimus and daclizumab to treat age-related macular degeneration [ClinicalTrials.gov identifier: NCT00304954]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00304954 [Accessed 2008 Feb 8]
38. Umeda N, Kachi S, Akiyama H, et al. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol 2006; 69 (6): 1820-8
39. Zahn G, Vossmeyer D, Stragies R, et al. JSM6427, a small molecule integrin alpha5beta1 inhibitor for inhibition of ocular angiogenesis [abstract no. E-3430]. Invest Ophthalmol Vis Sci 2007; 48 (5) [online]. Available from URL: http://www.iovs.org/search.dtl?arvomtgsearch=true [Accessed 2008 Mar 7]